X4 PHARMACEUTICALS, INC Lessee, Operating Lease, Liability, Undiscounted Excess Amount
X4 PHARMACEUTICALS, INC (XFOR) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $13.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-08-06
- 2026-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $13.00K.
- 2026-03-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $32.00K.
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $58.00K.
- 2025-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $91.00K.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2026-06-30 | $13.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $32.00K 10-Q · filed 2026-05-06 |
| 2025-12-31 | $58.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | $91.00K 10-Q · filed 2025-11-05 |
| 2025-06-30 | $248.00K 10-Q · filed 2025-08-08 |
| 2025-03-31 | $306.00K 10-Q · filed 2025-05-01 |
| 2024-12-31 | $374.00K 10-K · filed 2025-03-26 |
| 2024-09-30 | $469.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $551.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $649.00K 10-Q · filed 2024-05-07 |
| 2023-12-31 | $758.00K 10-K · filed 2024-03-21 |
| 2023-09-30 | $858.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $984.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $1.11M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $1.24M 10-K · filed 2023-03-21 |
| 2022-09-30 | $1.35M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $1.52M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.70M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $1.87M 10-K · filed 2022-03-17 |
| 2021-09-30 | $2.05M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $2.24M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $2.48M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $1.90M 10-K · filed 2021-03-19 |
| 2020-09-30 | $2.05M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $275.00K 10-Q · filed 2020-08-04 |
| 2020-03-31 | $365.00K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $423.00K 10-K · filed 2020-03-12 |
| 2019-09-30 | $454.00K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $522.00K 10-Q · filed 2019-08-07 |
| 2019-03-31 | $764.00K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |